IC
ICCC.US ImmuCell Corporation
- Market cap
- USD 97.7M
- P/E
- 56.6x
- P/B
- 2.98x
- ROE
- 19.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ICCC.US undervalued?
Graham numberICCC.US trades 173.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImmuCell Corporation fundamental analysis
No fundamental analysis for ImmuCell Corporation yet.
ImmuCell Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment o…
Full company profileImmuCell Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ImmuCell Corporation annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.54M | 10.4M | 11.0M | 13.7M | 15.3M | 19.2M | 18.6M | 17.5M | 26.5M | 27.6M | 34.1M |
| Gross Profit | 5.42M | 5.22M | 5.19M | 6.74M | 6.86M | 8.66M | 7.65M | 4.40M | 7.94M | 11.4M | 14.2M |
| Operating Income | 890K | -243K | -1.45M | -954K | -1.38M | 257K | -2.30M | -5.75M | -1.64M | 1.65M | 6.48M |
| EBITDA | 1.72M | 661K | 88.4K | 1.31M | 967K | 2.70M | 189K | -2.50M | 1.07M | 2.14M | 8.69M |
| Net Income | 508K | -168K | -2.32M | -1.30M | -1.02M | -78.3K | -2.49M | -5.77M | -2.16M | -1.04M | 6.31M |
| EPS | 0.12 | -0.03 | -0.42 | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | -0.26 | -0.12 | 0.68 |
| Balance Sheet | |||||||||||
| Total Assets | 24.7M | 34.3M | 32.7M | 38.7M | 40.4M | 44.5M | 44.9M | 43.8M | 45.1M | 42.5M | 48.0M |
| Total Liabilities | 4.98M | 10.7M | 11.0M | 9.70M | 12.1M | 11.9M | 14.5M | 18.8M | 17.6M | 15.5M | 15.2M |
| Shareholders' Equity | 19.7M | 23.6M | 21.7M | 29.0M | 28.3M | 32.6M | 30.4M | 25.0M | 27.5M | 27.1M | 32.8M |
| Cash & Short-term Investments | 10.6M | 3.80M | 2.52M | 8.77M | 7.95M | 10.2M | 5.79M | 979K | 3.76M | 3.81M | 7.91M |
| Total Debt | 3.05M | 8.96M | 9.77M | 8.42M | 10.7M | 10.3M | 12.5M | 16.7M | 15.1M | 13.2M | 12.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -324K | 1.18M | -373K | 234K | 1.32M | 954K | -1.54M | -4.67M | 358K | 2.48M | 9.80M |
| Capital Expenditure | 3.59M | 17.8M | 2.03M | 1.39M | 4.07M | 2.61M | 3.98M | 1.89M | 466K | 1.25M | 3.01M |
| Free Cash Flow | -3.91M | -16.6M | -2.40M | -1.16M | -2.76M | -1.65M | -5.52M | -6.57M | -108K | 1.22M | 6.79M |
| Ratios | |||||||||||
| ROE | 2.6% | -0.7% | -10.7% | -4.5% | -3.6% | -0.2% | -8.2% | -23.1% | -7.8% | -3.8% | 19.2% |
| ROA | 2.1% | -0.5% | -7.1% | -3.3% | -2.5% | -0.2% | -5.6% | -13.2% | -4.8% | -2.4% | 13.1% |
| Net Profit Margin | 5.3% | -1.6% | -21.1% | -9.4% | -6.7% | -0.4% | -13.4% | -33.1% | -8.1% | -3.8% | 18.5% |
| Debt to Equity | 0.15x | 0.38x | 0.45x | 0.29x | 0.38x | 0.32x | 0.41x | 0.67x | 0.55x | 0.49x | 0.37x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ImmuCell Corporation dividends
ImmuCell Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jul 25, 1990.
Who owns ImmuCell Corporation
- Insiders 32.09%
- Institutions 20.39%
- Public & others 47.52%
- Shares outstanding 9.09M
- Free float 6.03M
Top funds holding ICCC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 181K | 1.99% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 32.4K | 0.36% | -2.67% | Sep 2026 |
| iShares Micro-Cap ETF | 19.2K | 0.21% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 2 Instl | 18.4K | 0.20% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 13.6K | 0.15% | 0.00% | Sep 2026 |
| Nationwide Bailard Sm Cp Val M | 10.1K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 9.45K | 0.10% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 5.17K | 0.06% | 0.00% | Sep 2026 |
| DFA U.S. Targeted Value I | 4.75K | 0.05% | 0.00% | Sep 2026 |
| MINT GLOBAL SMALL CAPS FIF ACOES | 4.25K | 0.05% | +17.08% | Jul 2026 |
| Dimensional Global Trgtd Value USD Acc | 3.60K | 0.04% | -0.42% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.35K | 0.04% | 0.00% | Aug 2026 |
| DFA U.S. Vector Equity I | 3.00K | 0.03% | +0.13% | Sep 2026 |
| Vanguard Balanced Index Inv | 2.90K | 0.03% | 0.00% | Sep 2026 |
| Dimensional US Targeted Value ETF | 2.78K | 0.03% | 0.00% | Oct 2026 |
| DFA US Core Equity Class F | 2.42K | 0.03% | 0.00% | Aug 2026 |
| DFA U.S. Core Equity 1 I | 2.37K | 0.03% | +426.67% | Sep 2026 |
| DFA US Sustainability Core 1 | 2.18K | 0.02% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 2.11K | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 1.92K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding ICCC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 268K | 2.95% | +3.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 234K | 2.57% | +5.50% | Jun 2026 |
| Renaissance Technologies Corp | 173K | 1.91% | +1.34% | Sep 2026 |
| Cresset Asset Management, LLC | 135K | 1.49% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 72.3K | 0.79% | +9.89% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 60.5K | 0.67% | +3.44% | Sep 2026 |
| Bleichroeder LP | 50.0K | 0.55% | -50.78% | Jun 2026 |
| Steadtrust LLC | 45.4K | 0.50% | -16.55% | Jun 2026 |
| Mesirow Fin Investmt Mgmt Intl Equity | 42.5K | 0.47% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 40.5K | 0.45% | +13.47% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 37.8K | 0.42% | -11.49% | Jun 2026 |
| Strategic Investment Advisors Inc | 33.7K | 0.37% | -8.92% | Sep 2026 |
| HighTower Advisors, LLC | 24.4K | 0.27% | 0.00% | Jun 2026 |
| BlackRock Inc | 22.9K | 0.25% | +25.70% | Jun 2026 |
| Jane Street Group LLC | 15.8K | 0.17% | 0.00% | Jun 2026 |
| Quadrature Capital Limited | 15.4K | 0.17% | 0.00% | Jun 2026 |
| Northern Trust Corp | 14.7K | 0.16% | -64.63% | Jun 2026 |
| Mercer Global Advisors Inc. | 12.0K | 0.13% | 0.00% | Jun 2026 |
| Bailard Inc | 10.1K | 0.11% | 0.00% | Sep 2026 |
| Militia Capital Management, LLC | 10.0K | 0.11% | -81.48% | Jun 2026 |
ImmuCell Corporation company profile
- Company name
- ImmuCell Corporation
- Ticker
- ICCC.US
- Exchange
- USA Stocks
- Listed since
- Apr 30, 1987
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- 56 Evergreen Drive, Portland, ME, United States, 04103
- Phone
- 207 878 2770
- Website
- immucell.com
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
ImmuCell Corporation management
6- Mr. Paul F. Olivier Te BoekhorstPresident, CEO & Director · born 1972
- Mr. Timothy C. FioriCFO, Secretary & Treasurer · born 1979
- Ms. Bobbi Jo BrockmannSenior Vice President of Sales & Marketing · born 1977
- Ms. Elizabeth S. ToothakerDirector of Finance & Administration and Controller
- Mr. A. Gustavo ScaffaSenior Director of Quality
- John W. ZinckgrafDirector of Product Development